Eli Lilly Zepbound Results - Search News

News

Zepbound beats Wegovy for weight loss

Reuters on MSN · 4d

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

The Wall Street Journal on MSN · 4d

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Yahoo Finance · 3d

Eli Lilly (NYSE:LLY) Announces Superior Weight Loss Results for Zepbound Over Wegovy

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside its participation at the European Congress on Obesity and publication in The New England Journal of Medicine.

Hosted on MSN4d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...

3d

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

10don MSN

Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results